Introduction: C4d, an early product in the classical/lectin complement pathway has shown potential in the evaluation of C3 glomerulopathy where its absence would support an alternative pathway abnormality. As autoimmune/genetic complement testing is not readily available to most parts of the world, glomerular C4d staining may serve as a useful additional step toward the diagnosis.

Methods: To test this hypothesis, C4d staining was performed on a large cohort of C3 glomerulopathy. Archival cases from 2011 to 2017 were reviewed and immunohistochemistry for C4d was performed, scored (scale of 0 to 3+), and correlated with the immunofluorescence and ultrastructural findings. Paraffin immunofluorescence was performed in cases of "discordant C4d" to unmask Igs.

Results: Twenty-seven cases of dense deposit disease (DDD) and 14 cases of C3 glomerulonephritis (C3GN) were retrieved. C4d demonstrated a range of staining intensities with negative/traces in only 22% of DDD and 64% of C3GN. Lower-intensity C4d staining (1 to 2+) was mostly concordant with similar amounts of Igs/C1q. Discordant 3+ staining was noted in approximately 50% of cases of DDD and 20% of cases of C3GN. Among them, paraffin immunofluorescence unmasked polyclonal Igs in 2 of 5 cases of DDD and 1 of 3 cases of C3GN.

Conclusion: This observational study suggests that the presence of glomerular C4d should not exclude a C3 glomerulopathy. In lower intensities, it appears to represent overlying classical/lectin pathway activation with concordant Ig/C1q deposits. A subset of cases, however, displays intense and discordant C4d staining, which raises the possibility of an associated lectin pathway abnormality, a potential future area of study.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506704PMC
http://dx.doi.org/10.1016/j.ekir.2019.02.006DOI Listing

Publication Analysis

Top Keywords

c4d staining
20
glomerular c4d
12
cases
9
exclude glomerulopathy
8
c4d
8
pathway abnormality
8
paraffin immunofluorescence
8
ddd cases
8
cases ddd
8
staining
7

Similar Publications

[Early-onset antibody-mediated rejection with fever as the main manifestation after bilateral lung transplantation: a case report].

Zhonghua Jie He He Hu Xi Za Zhi

December 2024

Department of Lung Transplantation, China-Japan Friendship Hospital; National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences,Beijing100029, China.

Antibody-mediated rejection (AMR) is a recognized cause of allograft dysfunction in lung transplant recipients due to the presence of donor-specific anti-human leukocyte antigen (HLA) antibodies (DSAs). Here, we reported that a 69-year-old woman with underlying connective tissue disease-associated interstitial lung disease (CTD-ILD) developed recurrent fever with elevated white blood cells, C-reactive protein (CRP) and new ground-glass opacities on chest computed tomography (CT) early after double lung transplantation. After a thorough investigation for infection, rejection and relapse of primary immune diseases, the patient was found to be panel-reactive antibody (PRA) positive and DSAs positive.

View Article and Find Full Text PDF

Background: Though infrequent, allograft nephrectomies are performed for early and late graft loss. The study aims to analyze the histopathologic characteristics of allograft nephrectomy specimens.

Materials And Methods: We conducted an observational study of 103 cases of allograft nephrectomies from 21 centers from 2013 to 2023.

View Article and Find Full Text PDF

Early and late antibody mediated rejection: Which game is the complement playing?

Transplant Rev (Orlando)

January 2025

Nephrology Unit, Parma University Hospital, & Department of Medicine and Surgery, University of Parma, Parma, Italy.

Article Synopsis
  • * Despite the known association with complement activation, evidence shows that microvascular inflammation and endothelial damage can occur independently of this system, particularly in late AMR (>6 months post-transplant).
  • * The review discusses differences in mechanisms and clinical features between early and late AMR, suggesting that treatment strategies should reflect these variations in underlying inflammatory processes and complement activation levels.
View Article and Find Full Text PDF

Introduction: Hyperacute rejection leading to hepatic necrosis or intrahepatic bile duct stricture in ABO incompatible living-donor liver transplant (ABO-i LDLT) has been reported many times. With the advent of rituximab, the incidence of these complications has decreased significantly. However, consecutive biliary disruption after ABO-i LDLT has rarely been reported.

View Article and Find Full Text PDF

Introduction: The role of complement system in late stage of IgA nephropathy (IgAN) remains unknown. We therefore investigated the effects of complement system on worsening kidney function in advanced (stage 4 CKD) IgAN.

Methods: Renal specimens of 69 IgAN patients who underwent renal biopsy during stage 4 CKD between 2010 and 2021, were stained using immunofluorescence (IF) and immunohistochemistry (IHC) for glomerular complement components.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!